US FDA approves first drug for fatty liver disease NASH | Reuters News Agency



Reuters was first to report on the FDA approving Madrigal Pharmaceuticals’ drug Rezdiffra, an oral drug to treat a fatty liver disease known as non-alcoholic steatohepatitis (NASH). The approval was the first of its kind. 

Market Impact

The company’s shares surged 24% in extended trading.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story


Source link